U-46619 Chemical Properties

Boiling point:

519.7±30.0 °C(Predicted)

Density 

1.092±0.06 g/cm3(Predicted)

Flash point:

-10 °C

storage temp. 

-20°C

solubility 

≥100 mg/mL in DMSO, ≥100 mg/mL in Ethanol, ≥100 mg/mL in DMF, ≥2 mg/mL in PBS pH 7.2

pka

4.76±0.10(Predicted)

form 

solution

color 

Colorless to light yellow

BRN 

4267334

Safety Information

Hazard Codes 

F,Xi

Risk Statements 

11-36-66-67

Safety Statements 

16-26

RIDADR 

UN 1231 3/PG 2

WGK Germany 

2

RTECS 

MJ9681090

F 

8-10-23

Toxicity

LD50 intravenous in mouse: 66ug/kg

MSDS

• Language:English Provider:SigmaAldrich

U-46619 Usage And Synthesis

Uses

U 46619 is a PGH2 analog that may be used as a thromboxane A2 (TP) receptor agonist affecting mitogenic growth of vascular smooth muscle in humans.

Biological Activity

PGH 2 (TXA 2 ) analog that is a potent and stable thromboxane A 2 (TP) receptor agonist (EC 50 = 0.035 μ M). Potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations. Activates ERK-1 and ERK-2 in HEK-293 cells expressing TP α and TP β receptors.

Biochem/physiol Actions

Thromboxane receptor agonist.

in vitro

u46619 showed a biphasic effect on human platelets. shape change and mlcp occurred at low concentrations of this compound (ec50 = 0.035 um and 0.057 um), whereas serotonin release, platelet at higher concentrations (ec50 = 0.536 um and 1.31 um). the effect on platelet shape change and mlcp is receptor mediated [3].

in vivo

u46619, through activation of eta and etb receptors, elicits renal cortical vasoconstriction and medullary vasodilation in the rat [2]. in conscious shr (spontaneously hypertensive rats), 1-100 nmol/kg u-46619 (i.c.v.) induced a dose-related increase in blood pressure but had no significant effect on heart rate [1].

storage

Store at -20°C

References

[1] sirén al, svartstrm-fraser m, paakkari i. central cardiovascular effects of the endoperoxide analogue u-46619 in rats. prostaglandins leukot med. 1985 mar; 17 (3): 381-6.
[2] hantz h, adesuyi a, adebayo o. differential effects of u46619 on renal regional hemodynamics in the rat: involvement of endothelin. j pharmacol exp ther. 2001 oct; 299 (1): 372-6.
[3] morinelli ta1, niewiarowski s, daniel jl, smith jb. receptor-mediated effects of a pgh2 analogue (u 46619) on human platelets. am j physiol. 1987 nov; 253 (5 pt 2): h1035-43.

U-46619(56985-40-1)Related Product Information

• 9,11-DIDEOXY-9ALPHA,11ALPHA-EPOXY-METHANOPROSTAGLANDIN F2ALPHA
• Bromadoline
• U 75875
• METHYLENECYCLOHEXANE
• ETHYLENE OXIDE
• DELTA17-U-46619
• 5-TRANS U-46619
• U-46619 [15-3H]-
• U-46619